A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk?

Clinical Infectious Diseases

Volumn 59, Issue 11, 2014, Pages 1655-1656

  Mangioni, Davide ^a   Muscatello, Antonio ^a   Sabbatini, Francesca ^a   Soria, Alessandro ^a   Rossi, Marianna ^a   Bisi, Luca ^a   Squillace, Nicola ^a   De Grandi, Carlo ^a   Gori, Andrea ^a   Bandera, Alessandra ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ETRAVIRINE; IMMUNOGLOBULIN G; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CASE REPORT; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID CULTURE; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; FEMALE; GENE MUTATION; GENOTYPING TECHNIQUE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIMB PAIN; LIMB WEAKNESS; LUMBAR PUNCTURE; MIDDLE AGED; NEUROIMAGING; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; VIRUS ESCAPE; VIRUS LOAD; VIRUS RESISTANCE; BRAIN; CEREBROSPINAL FLUID; HIV INFECTIONS; PATHOLOGY; VIROLOGY;

ANTI-RETROVIRAL AGENTS; BRAIN; FEMALE; HIV INFECTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 84924403930     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu679     Document Type: Letter

References (9)

1. Canestri A, Lescure F, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving sup-pressive antiretroviral therapy. Clin Infect Dis 2010; 50: 773-8.
2. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202: 1819-25.
3. Garveya LJ, Everittc A, Winstona A, Mackie NE, Benzie A. Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment. AIDS 2009; 23: 1443-51.
4. Bogoch II, Davis BT, Venna N. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect 2011; 63: 236-9.
5. Katlama C, Galantina MA, Algarte-Genina M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365-74.
6. Gisslen M, Fuchs D, Hagberg L, Svennerholm B, Zetterberg H. Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis 2012; 44: 997-1000.
7. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010; 18: 45-55.
8. Ciccarelli N, Fabbiani M, Colafigli M, et al. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther 2013; 18: 153-60.
9. Burgos J, Crespo M, Falcó V, et al. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. J Antimicrob Chemother 2012; 67: 2479-86.